언론에 비친 KCS
후원사 혜택 안내
지면 광고 안내
소개 및 활동/사업
현재 가능한 작업은 아래와 같습니다.
02월 23일 15시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능
A novel PPARγ agonist KR62980 modulates both resorption and formation of bone while preventing bone loss in vivo mice models
2009년 2월 25일 11시 05분 46초
이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
목 15시 : 40분
Drug Discovery for Prevention of Aging and Improvement in Quality of Life
한국화학연구원 신약플랫폼 기술팀, Korea
The PPARγ nuclear receptor regulates osteoblast-adipocyte fate choice (inducing adipocytic while inhibiting osteoblastic differentiation) We have previously reported that KR62980, a new selective novel peroxisome proliferator-activated receptor g modulator, currently development for management of type 2 diabetes mellitus. In this study, we investigated whether KR62980 exhibits any effects on regulation of bone mass including osteoclastogenesis and osteoblastogenes. KR62980 induced alkaline phosphatase (ALP) activity and increased extracellular matrix calcification in osteoprogenitor calvaria-derived primary cells and MC3T3E1 cells. Real time RT-PCR analysis revealed that KR62980 also increased the mRNA transcripts of specific genes involved in osteoblastic differentiation, including bone sialoprotein (BSP), osteocalcin (OC), alkaline phosphatase, Runx-2, and PPAR1. However, KR62980 did not upregulate PPAR2 and ap2 associated with adipocyte differentiation in primary preosteoblastic cells. Furthermore, using an ex vivo neonatal clvaria implantation system, we showed that KR62980 enhanced the osteogenic activity for new bone formation. In addition, in order to examine if the KR62980 is related to an interference with osteoclast differentiation, we incubated human peripheral blood mononuclear cells (PBMC) with Wyeth 14643, ciprofibrate, gamma-linoleic acid and EPA in addition to osteoclast differentiating factors, RANK-L, MCSF and dexametazone. In addition, KR62980 was related to an interference with osteoclast differentiation. We incubated mouse bone marrow mononuclear cells (BMM) with osteoclast differentiating factors, RANK-L, MCSF and dexametazone. Bone mineral content and density (BMC and BMD, respectively) were measured in femur by X-ray computed microtomography (microCT). KR62980 treatment increased BMC and BMD of femur to a greater extent in ovariectomy (OVX) of mice. Furthermore, when bone marrow cells from each group were used to isolate osteoblast progenitors, KR62980 treated group exhibited the highest level of calcium mineralization, as assessed by Alizarin Red staining, and ALP activity using ALP activity staining kit. Taken together, these results suggest that KR62980 may have potential as a drug candidate for treating bone diseases in vivo and in vitro.
등록된 그림이 있는경우 그림을 클릭하시면 원본 그림파일을 볼 수 있습니다.
최종본을 확인하지 않아 발생된 문제에 대해서는 책임지지 않습니다.
미리보기의 그림위치는 임시 위치입니다. 모든 그림파일은 Abstract 하단에 위치하게 됩니다.